drugset

drugset / Trial / NCT02667574

Study Evaluating the Interest of Vismodegib as Neo-adjuvant Treatment of Basal Cell Carcinoma (BCC)

NCT02667574 ↗

Phase 2 Completed 55 enrolled University Hospital, Lille Hoffmann-La Roche · collab

NaSingle-groupOpen-labelTreatment

Summary

Open-label, non-comparative, multicenter, phase II study of Vismodegib in patients with locally advanced BCC.

Timeline

Start: 2014-11-18
Primary completion: 2020-07-15
Completion: 2020-07-15

Publications

Results Bertrand N, Guerreschi P, Basset-Seguin N, Saiag P, Dupuy A, Dalac-Rat S, Dziwniel V, Depoortere C, Duhamel A, Mortier L. Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study): Neoadjuvant Vismodegib in Locally Advanced Basal Cell Carcinoma. EClinicalMedicine. 2021 Apr 26;35:100844. doi: 10.1016/j.eclinm.2021.100844. eCollection 2021 May.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Vismodegib	Small molecule	150 mg	Oral

Indications